K W Garey

Summary

Affiliation: University of Houston
Country: USA

Publications

  1. ncbi Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea
    Q M Yeo
    National University of Singapore, Singapore
    Drugs Today (Barc) 49:239-52. 2013
  2. ncbi A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection
    Kevin W Garey
    University of Houston College of Pharmacy, Houston, TX 77030, USA
    J Antimicrob Chemother 66:2850-5. 2011
  3. ncbi Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients
    K W Garey
    University of Houston, 1441 Moursund Street, Houston, TX 77030, USA
    J Chemother 18:402-8. 2006
  4. ncbi Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin
    Kevin W Garey
    University of Houston College of Pharmacy, Department of Clinical Sciences and Administration, Houston, TX 77030, USA
    Diagn Microbiol Infect Dis 63:81-6. 2009
  5. ncbi Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
    K W Garey
    University of Houston College of Pharmacy, Houston, TX 77030, USA
    J Hosp Infect 70:298-304. 2008
  6. ncbi A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics
    K W Garey
    University of Houston College of Pharmacy, Houston, TX, USA
    J Hosp Infect 70:142-7. 2008
  7. ncbi Peripartum Clostridium difficile infection: case series and review of the literature
    Kevin W Garey
    Texas Medical Center, University of Houston College of Pharmacy, Houston, TX 77030, USA
    Am J Obstet Gynecol 199:332-7. 2008
  8. ncbi Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines
    Kevin W Garey
    University of Houston, Houston, TX 77030, USA
    Pharmacoepidemiol Drug Saf 16:919-27. 2007
  9. ncbi Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
    Kevin W Garey
    Texas Medical Center, University of Houston, 1441 Moursund Street, Houston, TX 77030, USA
    Int J Antimicrob Agents 29:557-62. 2007
  10. ncbi Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea
    Kevin W Garey
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX 77030, USA
    Ann Pharmacother 42:827-35. 2008

Collaborators

Detail Information

Publications57

  1. ncbi Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea
    Q M Yeo
    National University of Singapore, Singapore
    Drugs Today (Barc) 49:239-52. 2013
    ..Crofelemer may be an important addition to the currently available drugs for the management of secretory diarrhea...
  2. ncbi A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection
    Kevin W Garey
    University of Houston College of Pharmacy, Houston, TX 77030, USA
    J Antimicrob Chemother 66:2850-5. 2011
    ..The purpose of this study was to assess rates of recurrent diarrhoea in patients with CDI given rifaximin versus placebo immediately after standard therapy...
  3. ncbi Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients
    K W Garey
    University of Houston, 1441 Moursund Street, Houston, TX 77030, USA
    J Chemother 18:402-8. 2006
    ..Risk factors associated with Gram-negative SWI were identified. Unique interventions may be necessary to prevent Gram-negative SWI in cardiac surgery patients...
  4. ncbi Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin
    Kevin W Garey
    University of Houston College of Pharmacy, Department of Clinical Sciences and Administration, Houston, TX 77030, USA
    Diagn Microbiol Infect Dis 63:81-6. 2009
    ..001) and 44 clinical P. aeruginosa strains (2 or 32 microg/mL, P<0.001). Clarithromycin increased bacterial adherence to the suspended coupons, and increased biomass was observed in isolates treated with clarithromycin...
  5. ncbi Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
    K W Garey
    University of Houston College of Pharmacy, Houston, TX 77030, USA
    J Hosp Infect 70:298-304. 2008
    ..Significant prognostic risk factors were identified as risk factors for CDI recurrence. Additional or novel interventions may be required for these patients to prevent CDI recurrence...
  6. ncbi A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics
    K W Garey
    University of Houston College of Pharmacy, Houston, TX, USA
    J Hosp Infect 70:142-7. 2008
    ..This easily implemented risk index should allow stratification of patients into risk group categories for development of CDI and help fashion preventive strategies...
  7. ncbi Peripartum Clostridium difficile infection: case series and review of the literature
    Kevin W Garey
    Texas Medical Center, University of Houston College of Pharmacy, Houston, TX 77030, USA
    Am J Obstet Gynecol 199:332-7. 2008
    ..Further research into the scope and risk factors for peripartum CDI is warranted...
  8. ncbi Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines
    Kevin W Garey
    University of Houston, Houston, TX 77030, USA
    Pharmacoepidemiol Drug Saf 16:919-27. 2007
    ..The objectives of this study were to assess the incidence of inappropriate fluconazole therapy in patients with candidemia and to identify variables associated with inappropriate therapy...
  9. ncbi Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
    Kevin W Garey
    Texas Medical Center, University of Houston, 1441 Moursund Street, Houston, TX 77030, USA
    Int J Antimicrob Agents 29:557-62. 2007
    ..0097). A delay or an inadequate dose or fluconazole in patients with candidaemia was associated with increased hospital costs. Improved methods to diagnose patients with candidaemia quickly are needed...
  10. ncbi Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea
    Kevin W Garey
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX 77030, USA
    Ann Pharmacother 42:827-35. 2008
    ..To review the existing data on use of the rifamycin class of antibiotics as therapy for Clostridium difficile-associated diarrhea (CDAD)...
  11. ncbi Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery
    Kevin W Garey
    University of Houston College of Pharmacy, Houston, Texas, USA
    Pharmacotherapy 28:699-706. 2008
    ....
  12. ncbi Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians
    Kimberly K Birtcher
    Department of Clinical Sciences and Administration DCSA, University of Houston College of Pharmacy UHCP, Houston, TX 77030, USA
    Am J Health Syst Pharm 67:231-8. 2010
    ....
  13. ncbi Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections
    Kevin W Garey
    University of Houston College of Pharmacy, Department of Clinical Sciences and Administration, Houston, TX 77030 3047, USA
    J Antimicrob Chemother 58:645-50. 2006
    ..The objective of the present study was to assess the effect of vancomycin prophylaxis timing in relation to the first surgical incision on the incidence of SSI...
  14. ncbi Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study
    Kevin W Garey
    Department of Clinical Science and Administration, University of Houston College of Pharmacy, Houston, TX, USA
    Clin Infect Dis 43:25-31. 2006
    ..The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality...
  15. ncbi Economic consequences of unused medications in Houston, Texas
    Kevin W Garey
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX 77030 3047, USA
    Ann Pharmacother 38:1165-8. 2004
    ..It is likely that a large amount of unused and outdated medications exists in households throughout the US; however, the amount and potential costs of these medications are unknown...
  16. ncbi A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection
    Kevin W Garey
    University of Houston College of Pharmacy, Houston, Texas, USA
    Clin Infect Dis 51:1406-10. 2010
    ..We hypothesized that a common single-nucleotide polymorphism (SNP) in the -251 region of the IL-8 gene promoter may be predictive of recurrent CDI...
  17. ncbi Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study
    Kevin W Garey
    Department of Clinical Science, University of Houston College of Pharmacy, Houston, TX 77008 3407, USA
    Mycoses 49:226-31. 2006
    ..Research efforts to identify patients who warrant preemptive antifungal therapy for invasive candidiasis could dramatically change antifungal prescribing patterns in the SICU...
  18. ncbi Prevalence of diarrhea at a university hospital and association with modifiable risk factors
    Kevin W Garey
    College of Pharmacy, Department of Clinical Sciences and Administration, University of Houston, and St Luke s Episcopal Hospital, TX 77030, USA
    Ann Pharmacother 40:1030-4. 2006
    ..To assess the prevalence of diarrhea at a university-affiliated medical center and the presence of modifiable risk factors...
  19. ncbi Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery
    K W Garey
    University of Houston, College of Pharmacy, Texas Medical Center, 1441 Moursund Street, Houston, TX 77030, USA
    Antimicrob Agents Chemother 52:446-51. 2008
    ....
  20. ncbi In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas
    Z D Jiang
    Center for Infectious Disease, University of Texas School of Public Health, Houston, Texas 77030, USA
    J Clin Pathol 63:355-8. 2010
    ..This was an in vitro study to analyse the susceptibility of Clostridium difficile isolates to rifampin and rifaximin...
  21. ncbi Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital
    M F Price
    St Luke s Episcopal Hospital, Houston, TX, USA
    J Hosp Infect 65:42-6. 2007
    ..Admitting physicians should consider C. difficile in the differential diagnosis of patients admitted with diarrhoea, with or without a history of admission to healthcare facilities...
  22. ncbi Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia
    K W Garey
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy Houston, TX 77030, USA
    J Chemother 20:714-20. 2008
    ..One of two type III secretion effector proteins were almost universally present in PSA bloodstream isolates. Isolates containing the exoU gene were more likely to be resistant to multiple antibiotics...
  23. ncbi High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection
    V Arora
    University of Houston College of Pharmacy, Houston, TX, USA
    J Hosp Infect 79:23-6. 2011
    ..3) days] than patients with scores of 1 or 2 [mean 15.1 (SD 16.2) days, P = 0.001]. This study found Horn's index to be a simple and useful method for identifying CDI patients at high risk of poor clinical and economic outcomes...
  24. ncbi Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes
    D N Shah
    University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    J Antimicrob Chemother 66:2146-51. 2011
    ..The purpose of this study was to assess antifungal therapy in hospitalized patients with candidaemia during the time period between the start of empirical therapy and after antifungal susceptibility testing reports are available...
  25. ncbi Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization
    Sumesh Kachroo
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, TX 77030, USA
    Ann Pharmacother 40:381-5. 2006
    ..CONCLUSIONS: Surgical antibiotic prophylaxis with vancomycin was reasonably well tolerated in CABG and valve replacement surgery, with a 4% incidence of VRE colonization...
  26. ncbi Economic healthcare costs of Clostridium difficile infection: a systematic review
    S S Ghantoji
    University of Texas School of Public Health, Houston, Texas, USA
    J Hosp Infect 74:309-18. 2010
    ..Economic healthcare costs of CDI were high for primary and recurrent cases. The high cost associated with CDI justifies the use of additional resources for CDI prevention and control...
  27. ncbi Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa
    V H Tam
    University of Houston College of Pharmacy, Houston, TX 77030, USA
    Clin Microbiol Infect 13:413-8. 2007
    ..aeruginosa. Understanding the prevalence and mechanisms of beta-lactam resistance in P. aeruginosa may guide the choice of empirical therapy for nosocomial infections in hospitals...
  28. ncbi Comparison of risk factors for candidemia versus bacteremia in hospitalized patients
    P P Amrutkar
    University of Houston, College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Infection 34:322-7. 2006
    ..These results can be used to help identify patients most likely to benefit from empiric antifungal therapy...
  29. ncbi Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis
    Darego O Maclayton
    Texas Southern University College of Pharmacy and Health Sciences, Houston, TX, USA
    Clin Ther 28:1208-16. 2006
    ..These patients experienced a longer mean hospital length of stay and increased hospital costs compared with patients with MRSA bacteremia with a vancomycin MIC < or =0.5 microg/mL and uninfected controls...
  30. ncbi Automated system to identify Clostridium difficile infection among hospitalised patients
    Y Yadav
    University of Texas School of Public Health, Houston, Texas, USA
    J Hosp Infect 72:337-41. 2009
    ..Using an electronic data capture technique, number of days of diarrhoea and maximum number of diarrhoea stools in a 24h time period were able to identify a patient population at high risk for CDI...
  31. ncbi High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis
    Hua Chen
    University of Houston, Houston, TX, USA
    Curr Med Res Opin 23:1057-65. 2007
    ..However, empiric high-dose fluconazole is not currently recommended and may result in higher drug costs and toxicity...
  32. ncbi Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes
    Vincent H Tam
    University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Antimicrob Agents Chemother 54:3717-22. 2010
    ..011). Multidrug resistance is a significant risk factor for 30-day mortality in patients with P. aeruginosa bacteremia; efforts to curb the spread of MDR P. aeruginosa could be beneficial...
  33. ncbi Crofelemer, a novel agent for treatment of secretory diarrhea
    Rustin D Crutchley
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX, USA
    Ann Pharmacother 44:878-84. 2010
    ..To review the chemistry, pharmacology, pharmacokinetics, efficacy, and safety of crofelemer...
  34. ncbi An integrated pharmacoeconomic approach to antimicrobial formulary decision-making
    Vincent H Tam
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy UHCP, Houston, TX 77030, USA
    Am J Health Syst Pharm 63:735-9. 2006
    ..The utility of a novel interdisciplinary approach to antimicrobial formulary decision-making was studied...
  35. ncbi Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea
    Zhi Dong Jiang
    Center for Infectious Diseases, 1200 Herman Pressler, Room 739, University of Texas School of Public Health, Houston, Texas 77030, USA
    Clin Gastroenterol Hepatol 5:964-8. 2007
    ..This study examined the relationship between serum immunoglobulin G antibodies to CD toxin A and the presence of IL-8 AA genotype in hospitalized patients with CDAD...
  36. ncbi Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections
    Jessica Cottreau
    University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Expert Rev Anti Infect Ther 8:747-60. 2010
    ..Finally, clinical trials with rifaximin for nonsystemic gastrointestinal indications will be updated...
  37. ncbi Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa
    Vincent H Tam
    University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Antimicrob Agents Chemother 54:1160-4. 2010
    ..Understanding and continuous monitoring of the prevalence and resistance mechanisms of MDR P. aeruginosa would enable us to formulate rational treatment strategies to combat nosocomial infections...
  38. ncbi Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance
    Dhara Shah
    University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Expert Rev Anti Infect Ther 8:555-64. 2010
    ..This review will focus primarily on scientific studies published in the last 36 months in order to provide an up-to-date review on the topic...
  39. ncbi Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia
    Vincent H Tam
    University of Houston College of Pharmacy, TX 77030, USA
    Diagn Microbiol Infect Dis 63:279-85. 2009
    ..3-720.0) and experience microbiologic persistence (OR = 12.2; 95% CI, 1.7-87.7). In institutions with a high prevalence of AmpC++, empiric therapy with agents with activity against AmpC++ strains may be warranted...
  40. ncbi Significant publications on infectious diseases pharmacotherapy in 2007
    Rosa F Yeh
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX 77030, USA
    Am J Health Syst Pharm 65:e72-9. 2008
    ..Significant publications on infectious diseases (ID) pharmacotherapy in 2007 were compiled and summarized...
  41. ncbi Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa
    Vincent H Tam
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX 77030, USA
    Diagn Microbiol Infect Dis 58:309-14. 2007
    ..aeruginosa. Understanding the prevalence and mechanism of carbapenem resistance in P. aeruginosa may guide empiric therapy for nosocomial infections in our hospital...
  42. ncbi Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint
    Vincent H Tam
    University of Houston College of Pharmacy, Houston, Texas 77030, USA
    Clin Infect Dis 46:862-7. 2008
    ..Recent studies have emphasized the importance of appropriate empirical therapy, but controversy arises when piperacillin-tazobactam is used against isolates with reduced susceptibility...
  43. ncbi Pharmacists' perceptions of the effectiveness of antimicrobial control programs
    Gail S Itokazu
    College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
    Am J Health Syst Pharm 63:2504-8. 2006
    ..The perceptions of the effectiveness of antimicrobial control programs (ACPs) among infectious diseases (ID) pharmacists were studied...
  44. ncbi Future novel therapeutic agents for Clostridium difficile infection
    Hoonmo L Koo
    Baylor College of Medicine, Internal Medicine, Houston, TX 77030, USA
    Expert Opin Investig Drugs 19:825-36. 2010
    ....
  45. ncbi Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital
    Miguel Salazar
    St Luke s Episcopal Hospital, Houston, TX 77030, USA
    Pharm World Sci 31:565-71. 2009
    ..To assess changes in testing and treatment trends of CDI at a time when the Clostridium difficile hypervirulent strain was first identified...
  46. ncbi Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections
    Laura Gerard
    University of Houston College of Pharmacy, TX 77030, USA
    Expert Rev Anti Infect Ther 3:201-11. 2005
    ..Importantly, rifaximin does not appear to lead to bacterial resistance. Rifaximin has an excellent safety profile and adverse drug reactions have been comparable to those associated with the placebo control agent...
  47. ncbi Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic
    Susan M Loughlin
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas 77030, USA
    Pharmacotherapy 27:729-33. 2007
    ..To determine whether a vaccination program in a pharmacist-managed secondary prevention lipid clinic increased influenza immunization rates in a high-risk population, and whether age or gender disparity existed among those vaccinated...
  48. ncbi Clostridium difficile-related death rates in Texas 1999-2005
    Miguel Salazar
    St Luke s Episcopal Hospital, TX, USA
    J Infect 59:303-7. 2009
    ..Increased incidence of Clostridium difficile infection and deaths from US hospitals has occurred from 1996 to 2005...
  49. ncbi Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection
    D N Shah
    University of Houston, College of Pharmacy, Houston, TX 77030, USA
    J Hosp Infect 83:294-9. 2013
    ..The Society for Healthcare Epidemiology of America (SHEA) and Infectious Disease Society of America (IDSA) guidelines define acute renal dysfunction as serum creatinine (SrCr) ≥1.5 times the premorbid level...
  50. ncbi Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature
    K W Garey
    Department of Pharmacy, College of Pharmacy, University of Illinois at Chicago, 60612-7320, USA
    Pharmacotherapy 21:855-60. 2001
    ..The patient's death, which occurred despite aggressive debridement and high amphotericin B lung concentrations, highlights the need for novel strategies to treat infections caused by invasive molds such as C. bertholletiae...
  51. ncbi Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent
    K Halton
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX, USA
    Clin Microbiol Infect 17:868-9. 2011
    ..A significant reduction in potential healthcare-associated pathogens, especially Gram-positive cocci, was observed in the intervention group...
  52. ncbi Significant publications on infectious diseases pharmacotherapy in 2009
    Hannah R Palmer
    St Luke s Episcopal Hospital, Houston, TX, USA
    Am J Health Syst Pharm 67:e34-42. 2010
    ..Significant publications on infectious diseases (ID) pharmacotherapy in 2009 are summarized...
  53. ncbi Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases
    Kevin W Garey
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX, USA
    Chest 123:261-5. 2003
    ..Long-term, low-dose administration of 14- and 15-membered ring macrolide antibiotics may represent an important adjunct in the treatment of chronic inflammatory sinopulmonary diseases in humans...
  54. ncbi Involvement of immunization-certified pharmacists with immunization activities
    Melinda M Neuhauser
    Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX 77030-3047, USA
    Ann Pharmacother 38:226-31. 2004
    ..CONCLUSIONS: Immunization-certified pharmacists are using their skills to administer vaccines to patients within their communities. Efforts to increase the number of these pharmacists throughout the US should be undertaken...
  55. ncbi Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone
    Katie J Suda
    Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA
    Pharm World Sci 27:81-2. 2005
    ..Health care professionals should be cognizant of these interactions and educated on their potential deleterious effect...
  56. ncbi Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia
    Manjunath P Pai
    University of New Mexico, Albuquerque, New Mexico, USA
    Antimicrob Agents Chemother 51:35-9. 2007
    ..09). These data support the dose-dependent properties of fluconazole. Underdosing fluconazole against less-susceptible Candida isolates has the potential to increase the risk of mortality associated with candidemia...
  57. ncbi Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration
    Susan L Pendland
    The University of Illinois at Chicago, Department of Pharmacy Practice, Chicago, IL, USA
    Diagn Microbiol Infect Dis 44:59-61. 2002
    ..In general, gatifloxacin demonstrated faster killing against Acinetobacter baumanii, Legionella pneumophila, Staphylococcus aureus, and Streptococcus pneumoniae...